GenXPro Research: No fear of the unknown

Research

Besides our service activities, we are also involved in several research projects to broaden our spectrum of techniques and know how within very different fileds of life sciences. We are currently members of the following research consortia:

FemNAT-CD – Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing

FemNAT-CD aims to understand the causes of sex differences in behaviour. The project will study similarities and differences between boys and girls in brain structure and function, hormone levels, genetics, emotion recognition and regulation, and physiological activity in 1,840 children and teenagers aged from 9 to 18 years from across Europe (including the UK, Germany, Ireland, Switzerland, the Netherlands, Spain, Greece and Hungary). We will also be conducting interviews with children and their parents to ask about the child’s health and behaviour, and trying to understand the impact of environmental factors on well-being. The study is funded by the European Commission’s 7th Framework Health programme, and involves scientific collaboration between 13 Universities and clinics across the Europe. The project is coordinated by Goethe University in Frankfurt, Germany.

List_MAPS – Training and research in Listeria monocytogenes adaptation through proteomic and transcriptome deep sequencing analysis

List_MAPS is an Innovative Training Network (ITN) funded by the Marie-Sklodowska Curie actions, working on the bacterium Listeria monocytogenes.

List_MAPS-couleur

Triple-T: Rationalized Tailored Targeted Therapy (Eurostars)

3-T combines the expertise of the University Medical Center Groningen, GenXPro GmbH and PamGene International BV in genomic and kinase activity profiling to provide doctors and patients with reliable information on druggable and drug-resistance pathways of individual lung tumors. 3-T establishes conceptual and technical innovations that will enable clinicians to rationally choose the best suited treatment for an individual patient with otherwise therapy resistant tumors. First results demonstrate the uniqueness of tumors and underpin the validity of the concept which can be extended also to other cancers

eurostars-logo

Antidote

legato_banner